Market Update - Global Market Expansion with Unique New Zealand Genetics
Global Market Expansion with Unique New Zealand Genetics
First Licence for Psilocybe (Magic Mushroom) Cultivation in NZ
Indigenous psilocybin clinial trials team, Rangiwaho Marae, July 2023. Copyright: Rangiwaho Marae
Shareholders and Community Engagement Day
Shareholders and Community Engagement Day 2023
Rua Bioscience launches first product in Australia
Rua Bioscience is positioned for growth, establishing collaborative networks and seizing opportunity in the booming Australian cannabis market.
2023 - Shareholder’s Annual Results
2023 Annual Shareholders’ Meeting and Director Nominations
Germany Brand Launch Event - Rua and Nimbus.
On a beautiful rooftop venue in Berlin, Germany, Rua Bioscience and Nimbus Health joined forces to co-host an unforgettable brand launch event. The evening was focused on sharing the Rua story with doctors, pharmacists and patients.
First Revenue from Germany
Shareholders Newsletter
Rua Bioscience Launches in Germany
Rua Bioscience has successfully launched its first medicine in Germany. In doing so, the company has become one of the first medicinal cannabis company in New Zealand to introduce a branded product in Europe’s largest medicinal cannabis market.
Rua Accelerates Export Strategy, Ceases Manufacturing
Rua Bioscience announces the export-led company will cease local GMP manufacturing and accelerate its global brand strategy, building its international product pipeline while developing valuable points of difference in the areas of genetic discovery and novel product development. Working with manufacturing partners, Rua expects New Zealand patients will ultimately benefit from a wider range of affordable medicines.
Rua Releases Market Insights 2023
Rua Bioscience has released its Market Insights for 2023.
The update is designed to share information about the challenges and opportunities presented by emerging high-value medicinal cannabis markets.
Rua Releases Half-Year Result – Results as expected, with German launch imminent
The Group reported a net profit after tax of $718,703 for the period ending 31 December 2022. Excluding fair value gain on contingent consideration of $4,100,932, the Group incurred an operating loss of $3,382,229.
The results are in line with expectations as the company established its product and revenue pipelines and further positioned itself to compete globally.
Rua Signs Supply Agreement, Targets Poland and Czechia
Rua Bioscience today announced it has signed a five-year master supply agreement with Motagon to supply medicinal cannabis products to Central and Eastern European countries. Critically, the agreement gives Rua access to the emerging medicinal cannabis markets of Czechia and Poland.
Update on the Impact of Cyclone Gabrielle
Rua Bioscience provides the following update on its operations in the wake of the regional disruptions caused by Cyclone Gabrielle.
Rua Announces Appointment of New CEO and Chair
Rua Bioscience has appointed Paul Naske as Chief Executive Officer. Interim Managing Director, Anna Stove, will return to Chair the Rua Board as Trevor Burt announces his retirement.
Rua Opens 2022 He Ara Atawhai – Undergraduate and Postgraduate Scholarships
Rua is now inviting specific East Coast kura to nominate students for our undergraduate scholarships as well as inviting all postgraduate students to apply for our postgraduate scholarships.
Rua Bioscience Confirms First International Order
Rua Bioscience Limited (NZX: RUA) formally announced today that it has received its first order via its German distributor Nimbus Health, marking a significant commercial milestone for the export-focused company.
Significant Headway Made with Trans-Tasman Medicinal Cannabis Partnership
Rua Bioscience’s cultivation partnership with Australian-based Cann Group is making significant headway; the two companies achieving key milestones this week.
